Delta-Fly Pharma Inc
TSE:4598
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Delta-Fly Pharma Inc
EPS (Diluted)
Delta-Fly Pharma Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Delta-Fly Pharma Inc
TSE:4598
|
EPS (Diluted)
-¥178
|
CAGR 3-Years
-2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
SanBio Co Ltd
TSE:4592
|
EPS (Diluted)
-¥47
|
CAGR 3-Years
5%
|
CAGR 5-Years
18%
|
CAGR 10-Years
-13%
|
|
|
GNI Group Ltd
TSE:2160
|
EPS (Diluted)
-¥80
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-16%
|
|
|
PeptiDream Inc
TSE:4587
|
EPS (Diluted)
-¥28
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Takara Bio Inc
TSE:4974
|
EPS (Diluted)
-¥59
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
EPS (Diluted)
-¥80
|
CAGR 3-Years
-6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
2%
|
|
Delta-Fly Pharma Inc
Glance View
Delta-Fly Pharma, Inc. engages in the manufacturing, sale, research and development of pharmaceutical products for cancer treatment. The company is headquartered in Tokushima-Shi, Tokushima-Ken and currently employs 11 full-time employees. The company went IPO on 2018-10-12. The firm's development pipeline includes anticancer drug candidate compound DFP-10917 whose target disease is refractory or recurrent acute myelogenous leukemia, anticancer drug candidate compound DFP-14323 whose target disease is lung cancer, anti-cancer drug candidate compound DFP-11207 whose target disease is solid cancer, anticancer drug candidate compound DFP-14927 whose target disease is solid cancer or blood cancer, anticancer drug candidate compound DFP-10825 whose target disease is peritoneal dissemination metastatic cancer.
See Also
What is Delta-Fly Pharma Inc's EPS (Diluted)?
EPS (Diluted)
-178.6
JPY
Based on the financial report for Mar 31, 2022, Delta-Fly Pharma Inc's EPS (Diluted) amounts to -178.6 JPY.
What is Delta-Fly Pharma Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
-2%
Over the last year, the EPS (Diluted) growth was 5%. The average annual EPS (Diluted) growth rates for Delta-Fly Pharma Inc have been -2% over the past three years .
